PATEL DINESH V PH D sold $14.9M of PTGX
PATEL DINESH V PH D (President and CEO) sold 100,000 shares of Protagonist Therapeutics, Inc (PTGX) at an average of $148.91 ($148.52–$149.11, $14.89M total) across 2 trades over 2026-08-10 to 2026-08-11 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The main tradable takeaway is the magnitude of insider selling disclosed today, which can influence short-term sentiment and positioning, but it does not change guidance, trial results, or corporate strategy in the text.
Market read
A large CEO sale ($14.89M) is newly disclosed, but the 10b5-1 framing suggests limited fundamental interpretation.
What to watch
The article does not state tax, diversification, or liquidity needs, and it provides no concurrent operational or clinical updates. Without those, the trading signal is mostly sentiment-based.
Background
This is an SEC Form 4 insider transaction: Protagonist Therapeutics CEO Dinesh V Patel sold shares in open-market trades under a 10b5-1 plan.
Ticker impact
PTGX CEO Dinesh V Patel sold about 100,000 shares in open-market trades for roughly $14.89M, per a new SEC Form 4 filed today.
Likely limited, short-lived sentiment impact; watch for follow-through only if additional insider selling or fundamental news appears.
Form 4 shows a pre-arranged 10b5-1 plan and the transaction is a sale, not a buy or corporate action. Size is notable, but 10b5-1 typically reduces interpretive weight versus discretionary selling.
Market effects
No sector-wide implication is stated; this is company-specific insider transaction disclosure.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, the market may overreact; the disclosure may have little predictive value for near-term fundamentals.
Key entities
- issuerProtagonist Therapeutics, Inc
Subject of the Form 4 insider sale disclosure.
- insiderPATEL DINESH V PH D
President and CEO who sold shares under a 10b5-1 plan.